

CERTIFICATE OF ANALYSIS

Important Note:	Centrifuge before opening to ensure complete recovery of vial contents.		
Catalog #:	A38104H	Lot #:	4E14422
Description:	Human Myeloperoxidase Human Myeloperoxidase (MPO)		
Source:	Human Neutrophil		
Format:	Purified, Liquid		
Purification:	> 96% pure (SDS-PAGE). Product is 0.2 µm filtered.		
Concentration:	Total Protein: 1.52 mg/mL (OD430nm, E ^{0.1%} = 1.19) Specific Activity: 1110 Units/mg Protein One unit of Myeloperoxidase will catalyze the consumption of one micromole of hydrogen peroxide and produce ¼ micromole of tetraguaiacol per minute at pH 7.0 and 25°C.		
Buffer:	50 mM Sodium Acetate, pH 6.0 containing 0.1 M Sodium Chloride.		
Preservative:	Bromo-nitro-dioxane and Methylisothiazolone.		
Applications:	Specific methodologies have not been tested using this product.		
Storage:	Store at 2–8°C.		
Inactivation:	Not Applicable		
Safety Note(s):	Refer to the appropriate Safety Data Sheet (SDS) for additional information.		
References:	The references listed below are for research purposes only: 1. Wilson, K.R., et al., (2007), "Defect in early lung defence against <i>Pseudomonas aeruginosa</i> in DBA/2 mice is associated with acute inflammatory lung injury and reduced bactericidal activity in naïve macrophages", <u>Microbiology</u> , 153 : 968-979. 2. Brennan, M.L., et al., (2003), "Value of MPO in Patients with Chest Pain", <u>New England Journal of Medicine</u> , 349 (17): 1595–1603. 3. Askari, A.T., et al., (2003), "MPO and Plasminogen Activator Inhibitor 1 Play a Central Role in Ventricular Remodeling after AMI", <u>Journal of Experimental Medicine</u> , 197 (5): 615–624. 4. Baldus, S., et al., (2003), "MPO Serum levels Predict Risk in Patients with Acute Coronary Syndromes", <u>Circulation</u> , 108 : 1440–1445.		

Quality Signature:



24 May 2022

FOR RESEARCH OR FURTHER MANUFACTURING USE ONLY